Erythromycin 100 mg tablets, No. 20 in a blister pack.

In stock: 2
$58.00

Ingredients

Active ingredient: erythromycin;

1 tablet contains 100 mg of erythromycin;

excipients: microcrystalline cellulose, croscarmellose sodium, sodium lauryl sulfate, colloidal anhydrous silicon dioxide, magnesium stearate.

Dosage Form

Tablets.

Main physical and chemical properties: round tablets, white or almost white, or white with a yellowish tint, with a biconvex surface. Slightly visible specks are permitted.

Pharmacotherapeutic group

Antibacterial agents for systemic use. Macrolides. Erythromycin. ATC code J01F A01.

Pharmacological Properties

Pharmacodynamics.

Erythromycin is a macrolide antibiotic with bacteriostatic action. At high concentrations and against highly susceptible microorganisms, it may have a bactericidal effect. It penetrates the bacterial cell membrane and reversibly binds to the 50S subunit of bacterial ribosomes; inhibits the translocation of peptides from the acceptor site of the ribosome to the donor site, thereby preventing further protein synthesis.

Active against Gram-positive bacteria: Streptococcus pyogenes, Streptococcus viridans, Streptococcus pneumoniae, Staphylococcus aureus, Corynebacterium diphtheriae, Corynebacterium minutissimum, Listeria monocytogenes; Gram-negative bacteria: Bordetella pertussis, Legionella pneumophila, certain strains of Haemophilus influenzae, Mycoplasma pneumoniae, as well as Entamoeba histolytica, Chlamydia trachomatis, and Treponema pallidum.

Gram-negative rods resistant to erythromycin include: Escherichia coli, Pseudomonas aeruginosa, as well as Shigella and Salmonella.

Pharmacokinetics.

It is absorbed in the gastrointestinal tract, with the rate of absorption depending on individual physiological characteristics. Bioavailability is 30–65%. Peak blood concentrations are reached 2 hours after administration. It is distributed throughout most tissues and body fluids, crosses the placental barrier, and passes into breast milk.

Plasma protein binding is 70–90%. It is metabolized in the liver, partly to form inactive metabolites. A significant portion of erythromycin is excreted from the body in bile, and only 2–5% is excreted unchanged in urine. The half-life is 1.4–2 hours with normal renal function.

Indications

Respiratory tract infections, including atypical pneumonia; ENT infections (tonsillitis, otitis, sinusitis); purulent-inflammatory diseases of the skin and its appendages, erythrasma, diphtheria, gonorrhea, syphilis, listeriosis, Legionnaires’ disease, infections in dentistry and ophthalmology, infections caused by microorganisms resistant to beta-lactam antibiotics, penicillin, tetracycline, levomycetin, chloramphenicol, and streptomycin.

Contraindications

  • Hypersensitivity to erythromycin or to any component of the drug, or to macrolides;
  • severe hepatic insufficiency;
  • a history of QT interval prolongation (congenital or acquired, documented) or ventricular arrhythmias, including “torsade de pointes”;
  • electrolyte imbalances (hypokalemia, hypomagnesemia—due to the risk of QT interval prolongation);
  • concomitant use with simvastatin, domperidone, tolterodine, misolastine, amisulpride, terfenadine, astemizole, pimozide, or cisapride, ergotamine, and dihydroergotamine;
  • concomitant use with lomitapide (see the section “Interactions with Other Medications and Other Types of Interactions”).

Interactions with Other Medications and Other Types of Interactions

The concomitant use of erythromycin is contraindicated with:

  • astemizole or terfenadine, cisapride, clarithromycin, or pimozide: increased risk of cardiotoxicity, including: QT interval prolongation, severe cardiac arrhythmias, including “torsade de pointes,” and cardiac arrest;
  • ergotamine or dihydroergotamine: acute toxicity reactions with vasospasm and dysesthesia are possible (erythromycin inhibits the metabolism of ergotamine and dihydroergotamine, exacerbating ergotamine-associated vasospasm).

The biotransformation of erythromycin occurs primarily in the liver via the cytochrome P450 system. Due to its effect on cytochrome P450 activity, erythromycin interacts with the following drugs:

  • theophylline, aminophylline, and caffeine: it increases their serum concentrations and toxicity—a reduction in the doses of these drugs and monitoring of their serum concentrations are necessary. It has been reported that when erythromycin is administered orally concomitantly with theophylline, a significant decrease in erythromycin serum concentrations is observed. This decrease may lead to subtherapeutic concentrations of erythromycin;
  • digoxin: increases its absorption and serum concentration;
  • cyclosporine: increases its concentration and enhances its nephrotoxicity;
  • carbamazepine: erythromycin may reduce its hepatic metabolism, allowing the carbamazepine dose to be reduced by up to 50% when the drugs are used concomitantly;
  • CYP3A4-inducing drugs (such as rifampicin, phenytoin, carbamazepine, phenobarbital, and St. John’s wort preparations): may induce the metabolism of erythromycin. This may lead to subtherapeutic levels of erythromycin in the blood and a reduction in its effect. Induction gradually subsides over two weeks after discontinuation of CYP3A4 inducers. Erythromycin should not be used for two weeks following treatment with CYP3A4 inducers;
  • corticosteroids: Caution is advised when erythromycin is used concomitantly with systemic and inhaled corticosteroids, which are primarily metabolized by CYP3A, due to a possible increase in systemic exposure to corticosteroids. Patients should be closely monitored for adverse reactions when systemic corticosteroids are used concomitantly;
  • phenytoin, alfentanil, methylprednisolone, benzodiazepines (such as triazolam, alprazolam, midazolam), hexobarbital, valproic acid, tacrolimus, rifabutin, zopiclone, bromocriptine, cabergoline: increases their concentrations and enhances their toxicity—dose adjustment of these drugs is necessary;
  • disopyramide, quinidine, procainamide: may prolong the QT interval or cause ventricular tachycardia;
  • oral contraceptives: increases the risk of their hepatotoxicity, reduces their effectiveness by interfering with the bacterial hydrolysis of steroid conjugates in the intestine and thereby reabsorbing the unconjugated steroid; as a result, plasma levels of the active steroid may decrease;
  • antifungal drugs: cardiotoxicity may develop (QT interval prolongation, paroxysmal ventricular tachycardia of the “pirouette” type) and, as a result, cardiac arrest. The use of this combination of drugs is contraindicated;
  • anticoagulants (warfarin, acetocoumarol): enhances their effects, which are more pronounced in the elderly. Therefore, prothrombin time should be monitored regularly; increased anticoagulant effects have been reported with the concomitant use of erythromycin and the oral anticoagulant rivaroxaban;
  • HMG-CoA reductase inhibitors: Erythromycin is contraindicated in patients receiving the HMG-CoA reductase inhibitors lovastatin and simvastatin (see the “Contraindications” section). It has been reported that erythromycin increases the plasma concentrations of HMG-CoA reductase inhibitors. Rare cases of rhabdomyolysis have also been reported in patients taking these medications concomitantly;
  • lomitapide: Concomitant use with erythromycin is contraindicated due to the potential for a significant increase in transaminase levels (see the “Special Precautions for Use” section);
  • sildenafil (Viagra): enhances its systemic effect—a reduction in the sildenafil dose is necessary;
  • calcium channel blockers, such as felodipine and verapamil: slows their elimination and enhances their effects. There have been reports of hypotension, bradyarrhythmia, and lactic acidosis when these drugs are taken concomitantly with erythromycin;
  • zafirlukast: reduces its concentration in blood plasma;
  • sulfonylureas, tetracycline, streptomycin: increased effect of erythromycin;
  • colchicine, vinblastine: toxicity has been reported when interacting with erythromycin;
  • cimetidine: increased risk of its toxicity, including reversible hearing loss;
  • levodopa (in combination with carbidopa): possible inhibition of carbidopa absorption and a decrease in plasma levodopa levels. In the case of such a combination, clinical monitoring is necessary. A dose adjustment of levodopa may be necessary;
  • bactericidal beta-lactam antibiotics (e.g., penicillin, cephalosporin): there is in vitro antagonism between erythromycin and bactericidal beta-lactam antibiotics;
  • clindamycin, lincomycin, and chloramphenicol: erythromycin counteracts their effects, and these drugs also inactivate erythromycin; therefore, they must not be used concomitantly with erythromycin. The same applies to streptomycin, tetracyclines, and colistin;
  • drugs that increase gastric acidity, as well as acidic beverages: these should not be used together, as they inactivate erythromycin;
  • protease inhibitors: when erythromycin is used concomitantly with protease inhibitors, the breakdown of erythromycin is inhibited;
  • hydroxychloroquine and chloroquine: erythromycin should be used with caution in patients receiving these medications, which are known to prolong the QT interval, due to the potential for inducing cardiac arrhythmias and serious adverse cardiovascular events.

The drug may affect the results of urine catecholamine measurements performed by the fluorometric method.

Special Considerations for Use

Before administering erythromycin, a detailed medical history should be obtained regarding hypersensitivity reactions to erythromycin, other macrolides, or other allergens. Rare serious allergic reactions, including acute generalized exanthematous pustulosis (AGEP), have been reported. If a hypersensitivity reaction develops in connection with the use of erythromycin, the drug should be discontinued immediately and symptomatic treatment initiated. Physicians should be aware that allergic symptoms may recur upon discontinuation of symptomatic therapy.

Before using the drug, it is advisable to identify the causative agent of the disease to reduce the risk of developing resistant bacterial strains. However, treatment with erythromycin may be initiated

before antibiotic susceptibility testing is performed; once the results are available, treatment should be continued or the drug should be replaced as appropriate.

Liver dysfunction, including elevated levels of “liver” enzymes in serum, hepatocellular and/or cholestatic hepatitis with or without jaundice, has been reported with the use of erythromycin preparations. Erythromycin is primarily excreted by the liver; therefore, it should be prescribed with caution to patients with impaired liver function, a history of jaundice, or those being treated with potentially hepatotoxic medications. Liver function should be monitored during long-term treatment with this medication or when taking high doses.

In patients with renal or hepatic insufficiency, as well as in elderly patients—due to age-related changes in liver and/or kidney function—the risk of ototoxicity is increased.

In patients who have received macrolides, including erythromycin, QT interval prolongation has been observed, reflecting an effect on cardiac repolarization and posing a risk of cardiac arrhythmias, including “torsade de pointes,” sometimes with fatal consequences.

Erythromycin should be used with caution in patients with ischemic heart disease, severe heart failure, conduction disturbances, or clinically significant bradycardia, and in patients (especially the elderly) who are concurrently taking other medications associated with QT interval prolongation.

Epidemiological studies investigating the risk of adverse cardiovascular outcomes associated with macrolide use have shown mixed results. Some observational studies have identified a small, short-term risk of arrhythmia, myocardial infarction, and cardiovascular mortality associated with macrolides, including erythromycin. Given these findings, a physician should evaluate the benefits and risks of treatment with erythromycin before prescribing it.

Due to the risk of adverse reactions such as QT interval prolongation on the ECG, the development of ventricular arrhythmias, including ventricular tachycardia and “torsade de pointes,” the drug should be prescribed with caution to patients with a history of arrhythmias.

Patients with bronchial asthma who are taking theophylline and erythromycin should be monitored, including assessment of theophylline levels in the blood to prevent toxicity.

This medication may exacerbate symptoms in patients with myasthenia gravis.

In severely ill patients taking lovastatin concomitantly with erythromycin, cases of rhabdomyolysis with or without renal failure have been observed. Therefore, if combination therapy with lovastatin or other HMG-CoA reductase inhibitors and erythromycin is necessary, the benefit-risk ratio must be carefully evaluated, monitor for symptoms such as muscle pain and weakness, and monitor serum levels of creatine kinase and transaminases.

Treatment with antibacterial drugs disrupts the normal flora of the large intestine and may lead to overgrowth of resistant strains of Clostridium difficile, whose toxins are the primary cause of pseudomembranous colitis. Pseudomembranous colitis can occur both during treatment and within 2 months after completion of antibiotic therapy. Cases of pseudomembranous colitis ranging from mild to life-threatening have been reported with the use of nearly all antibacterial drugs. Therefore, it is important to consider the possibility of pseudomembranous colitis in patients with diarrhea following antibiotic use. In mild cases, discontinuing the drug is usually sufficient; in severe cases, metronidazole or vancomycin should be prescribed. Agents that slow intestinal peristalsis are contraindicated.

Prolonged or repeated use of erythromycin, as with other antibacterial drugs, may lead to overgrowth of resistant microorganisms, particularly fungi. If a superinfection develops during treatment, erythromycin administration must be discontinued and appropriate measures taken.

When treating syphilis in pregnant women, it is important to note that the drug does not reach therapeutic concentrations in the fetus; therefore, after the baby is born, penicillin should be administered to infants whose mothers received erythromycin.

Cases of hypertrophic pyloric stenosis in infants (IHPS) have been reported following erythromycin therapy. Epidemiological studies, including data from meta-analyses, suggest a 2- to 3-fold increase in the risk of IHPS, particularly during the first 14 days of life. Available data indicate a risk of 2.6% (95% CI: 1.5–4.2%) following exposure to erythromycin during this time period. The risk of IHPS in the general population is 0.1–0.2%.

This medication may interfere with the results of fluorometric assays for catecholamines in urine.

Medications that increase gastric acidity, as well as acidic beverages, inactivate erythromycin. Erythromycin should not be taken with milk or dairy products.

The drug contains sodium (croscarmellose sodium, sodium lauryl sulfate), which should be taken into account by patients on a sodium-restricted diet.

Use during pregnancy or breastfeeding.

The available results of epidemiological studies on the risk of serious congenital malformations associated with the use of macrolides, including erythromycin, during pregnancy are conflicting. Some observational studies in humans have reported cardiovascular malformations following exposure to erythromycin-containing medications during early pregnancy.

The drug crosses the placenta, but fetal serum concentrations are low.

It has been reported that maternal use of macrolide antibiotics within 10 weeks after delivery increases the risk of hypertrophic pyloric stenosis (IHPS) in infants.

Erythromycin should be used by women during pregnancy only when absolutely necessary.

Erythromycin passes into breast milk; therefore, breastfeeding should be discontinued during treatment.

Effect on reaction time when driving or operating machinery.

Given the possibility of adverse reactions (dizziness, hallucinations, seizures, confusion, reversible hearing loss), patients should refrain from driving or operating machinery while taking this medication.

Dosage and Administration

The dose should be determined individually, depending on the location and severity of the infection, as well as the sensitivity of the pathogen.

Take orally 1–1.5 hours before or 2–3 hours after a meal.

Adults: 200–500 mg 4 times daily; maximum single dose: 500 mg; maximum daily dose: 2 g.

Children: 30 to 50 mg/kg of body weight per day, divided into 4 doses every 6 hours;

ages 3 to 6 years—500–700 mg per day;

ages 6 to 8 years—700 mg per day;

ages 8 to 14 years—up to 1 g per day, divided into 4 doses;

ages 14 and older – adult dose.

No dosage adjustment is required for elderly patients; monitoring of liver function is recommended due to the possibility of liver dysfunction in this age group.

The course of treatment is 5–14 days; continue taking the medication for an additional 2 days after symptoms have resolved.

Children.

Administer the drug to children aged 3 years and older according to the recommendations in the “Dosage and Administration” section.

Overdose

Symptoms: nausea, vomiting, diarrhea, and abdominal discomfort; liver dysfunction, possibly leading to acute liver failure; hearing loss, tinnitus, dizziness (especially in patients with renal and/or hepatic insufficiency).

Treatment: gastric lavage, administration of activated charcoal, symptomatic treatment. Hemodialysis, peritoneal dialysis, and forced diuresis are not effective.

Side Effects

Blood and lymphatic system: agranulocytosis, eosinophilia.

Cardiovascular system: QT interval prolongation on the ECG, palpitations, ventricular arrhythmias, including ventricular tachycardia, ventricular fibrillation and “torsade de pointes”-type arrhythmia, cardiac arrest.

Ear and balance organs: hearing loss and/or tinnitus, which resolves after discontinuation of the drug. There have been isolated reports of reversible hearing loss, primarily in patients with renal insufficiency and in patients receiving high doses of erythromycin (more than 4 g/day).

Gastrointestinal tract: The most common adverse reactions associated with oral erythromycin preparations are dose-dependent gastrointestinal disturbances. The following reactions have been reported: epigastric pain, nausea, vomiting, diarrhea, pancreatitis, anorexia, and hypertrophic pyloric stenosis in children. Cases of pseudomembranous colitis have been rarely reported.

General disorders and administration site conditions: chest pain, fever, malaise.

Hepatobiliary system: cholestatic hepatitis, jaundice, hepatic dysfunction, hepatomegaly, hepatic failure, hepatocellular hepatitis.

Immune system: allergic reactions, including anaphylactic reactions, such as anaphylactic shock.

Laboratory tests: elevated levels of “liver” enzymes in serum.

Nervous system: There have been isolated reports of transient adverse reactions of the central nervous system, including confusion, seizures, dizziness, and nightmares; however, a causal relationship has not been reliably established.

Psychiatric disorders: hallucinations.

Eyes: mitochondrial optic neuropathy.

Urinary system: interstitial nephritis.

Skin and subcutaneous tissue: skin rash, itching, hives, exanthema, angioedema, Stevens-Johnson syndrome, toxic epidermal necrolysis, erythema multiforme; acute generalized exanthematous pustulosis (AGEP).

Vascular system: hypotension.

Infections and parasitic diseases: During long-term or repeated courses of erythromycin therapy, a superinfection caused by drug-resistant bacteria may develop.

Other: effects due to chemotherapeutic action: oral candidiasis, vaginal candidiasis; onset of symptoms of myasthenic syndrome or exacerbation of existing myasthenia gravis.

Shelf life

3 years.

Storage conditions

Store in the original packaging at a temperature not exceeding 25 °C.

Keep out of reach of children.

Packaging

20 tablets per blister pack, 1 blister pack per box.

 

Manufacturer

Public Joint-Stock Company “Scientific and Production Center ‘Borshchahivsky Chemical and Pharmaceutical Plant’.”

Manufacturer’s location and address of its place of business.

Ukraine, 03134, Kyiv, 17 Myru St.